Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

AbbVie receives two FDA breakthrough designations for Temab-A

AbbVie receives two FDA breakthrough designations for Temab-A

AbbVie, the pharmaceutical company, has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration for a drug called telisotuzumab adizutecan, sold under the brand name Temab-A. This drug is being studied for its potential to significantly improve outcomes in two types of advanced solid tumors.

The first designation is for Temab-A combined with another drug, bevacizumab, in treating adults with a type of colorectal cancer that has not responded to previous treatments. This includes chemotherapy drugs such as fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF monoclonal antibody, and sometimes anti-EGFR monoclonal antibody therapy.

The second designation is for Temab-A alone, as a monotherapy, for adults with non-small cell lung cancer. This type of lung cancer is characterized by the presence of a specific protein (c-Met) and lacks a mutation in the EGFR gene. Patients in this category have already undergone treatment with platinum-based chemotherapy and an antibody therapy that targets the PD-(L)1 protein.

These designations were primarily based on results from a first-in-human study called M21-404. This is the first time Temab-A has received such designations from the FDA. Temab-A is an experimental drug that works by targeting the c-Met protein with a payload that inhibits a type of enzyme called topoisomerase 1. The drug's safety and efficacy have not been approved by global regulatory authorities.

AbbVie is currently exploring Temab-A's potential in a variety of advanced solid tumors, including head and neck squamous cell carcinoma, gastroesophageal adenocarcinoma, pancreatic ductal adenocarcinoma, and ovarian cancer. The company is conducting multiple phase 3 and phase 2/3 clinical trials to evaluate Temab-A's effectiveness as a standalone treatment and in combination with other therapies.

The FDA's Breakthrough Therapy Designation program aims to speed up the development and review process for drugs that show promise in treating serious conditions.

Rewritten by urgent.news; may contain errors — check the original.

Read the original at investing.com →

Report a problem with this story

More in Health & Medicine

Nabdam District Assembly sponsors free rabies vaccination for pets

By Peter Agengre More than 250 dogs have been vaccinated in the Nabdam District of the Upper East Region as part of activities to mark World Rabies Day. The three-day exercise, sponsored by the Nabdam District Assembly, was aimed at raising awareness about rabies and encouraging responsible pet ownership through regular vaccination.

More from Wednesday 7 October →